Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
January 26 2022 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announces the appointment of Cintia
Piccina as Chief Commercial Officer effective January 31, 2022.
“I am delighted to welcome Cintia to our leadership team. She
brings extensive commercial experience, including in cell and gene
therapy, that will be key as we prepare to submit our first BLA for
afami-cel this year, and build our commercial capabilities to
support the launch of this initial product and future next-gen cell
therapies within our MAGE-A4 franchise. Her fresh perspective and
leadership abilities will support our continued growth in our
mission to design and develop cell therapies for people with
cancer,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive
Officer.
Most recently, Cintia served as the Head of Commercial at
2Seventy Bio (Nasdaq:TSVT) and as SVP Commercial Oncology and US
General Manager, leading the launch of the first cell therapy
product in multiple myeloma, Abecma (idecabtagene vicleucel), for
bluebird bio (Nasdaq:BLUE). Before that she spent over 20 years at
Novartis (SIX:NOVN; NYSE:NVS) from 1997 to April 2020, first in
Brazil then in the United States, where she held a series of
commercial, marketing and sales roles across multiple therapeutic
areas including oncology. In her final role at Novartis, Cintia was
VP, Global Oncology Cell and Gene Strategy & Program Management
Office, for Kymriah and the CAR-T pipeline, leading the
cross-functional leadership teams for business (marketing, medical
affairs, market access), manufacturing, and pipeline. Cintia holds
a Doctorate in Pharmacy and Biochemistry from the University of Sao
Paulo, Brazil, and an MBA from the Escola Superior de Propaganda e
Marketing, Sao Paulo.
About Adaptimmune Adaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking Statements This release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission
(SEC) on November 4, 2021, and our other SEC
filings. The forward-looking statements contained in this
press release speak only as of the date the statements were made
and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or
circumstances.
Adaptimmune Contacts: Media
Relations: Sébastien Desprez — VP, Corporate
Affairs and Communications T: +44 1235 430 583 M: +44
7718 453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D.
— VP, Investor Relations T: +1 215 825 9310 M: +1
215 460 8920 Juli.Miller@adaptimmune.com
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024